Beta-Methylfentanyl

β-Methylfentanyl
Clinical data
Other namesβ-Methylfentanyl
ATC code
  • none
Legal status
Legal status
Identifiers
IUPAC name
  • N-Phenyl-N-[1-(2-phenylpropyl)piperidin-4-yl]propanamide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC23H30N2O
Molar mass350.506 g·mol−1
3D model (JSmol)
SMILES
  • O=C(N(c1ccccc1)C3CCN(CC(c2ccccc2)C)CC3)CC
InChI
  • InChI=1S/C23H30N2O/c1-3-23(26)25(21-12-8-5-9-13-21)22-14-16-24(17-15-22)18-19(2)20-10-6-4-7-11-20/h4-13,19,22H,3,14-18H2,1-2H3 checkY
  • Key:UXIGUKSHASXDNI-UHFFFAOYSA-N checkY
  (verify)

β-Methylfentanyl is an opioid analgesic that is an analogue of fentanyl.

β-Methylfentanyl was sold briefly on the black market in the early 1980s, before the introduction of the Federal Analog Act which, for the first time, attempted to control entire families of drugs based on their structural similarity rather than scheduling each drug individually as they appeared.[2]

β-Methylfentanyl has similar effects to fentanyl.[3] Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.[4]

References

  1. ↑ Drug Enforecement Administration, Department of Justice (February 2018). "Schedules of Controlled Substances:Temporary Placement of Fentanyl-Related Substances in Schedule I. Temporary amendment; temporary scheduling order". Federal Register. 83 (25): 5188–92. PMID 29932611.
  2. ↑ Henderson GL (March 1988). "Designer drugs: past history and future prospects". Journal of Forensic Sciences. 33 (2): 569–75. doi:10.1520/JFS11976J. PMID 3286815.
  3. ↑ "3-Methylfentanyl". www.drugbank.ca. Retrieved 2020-07-25.
  4. ↑ Mounteney J, Giraudon I, Denissov G, Griffiths P (July 2015). "Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe". The International Journal on Drug Policy. 26 (7): 626–31. doi:10.1016/j.drugpo.2015.04.003. PMID 25976511.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.